3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
3
Breast
2
Gynecologic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
44
Urinary Bladder Neoplasms
42
Testicular Neoplasms
30
Carcinoma, Transitional Cell
30
Ovarian Neoplasms
28
Testicular Germ Cell Tumor
16
Carcinoma, Non-Small-Cell Lung
14
Melanoma
11
Kidney Neoplasms
11
Carcinoma, Renal Cell
11
Breast Neoplasms
11
Wilms Tumor
10
Urethral Neoplasms
10
Teratoma
10
Sarcoma
10
Pancreatic Neoplasms
10
Central Nervous System Neoplasms
10
Colorectal Neoplasms
9
Neuroectodermal Tumors, Primitive, Peripheral
8
Neoplasm Metastasis
8
Stomach Neoplasms
7
Ovarian Germ Cell Cancer
7
Neoplasms
7
Seminoma
6
Osteosarcoma
6
Neuroblastoma
6
Lung Neoplasms
6
Head and Neck Neoplasms
6
Ureteral Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Interventions
talazoparib
1
olaparib
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fanconi Anemia, Complementation Group D1
×
Carboplatin
×
Genitourinary
×
Clear all
NCT04038502
2025-08-20
COBRA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled